Press releases
- Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
- Orexo Q1 2024 Interim Report
- Report from Orexo AB's annual general meeting, 26 April 2024
- Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo publishes the Annual and Sustainability Report for 2023
- Correction: Notice of Annual General Meeting of Orexo
More ▼
Key statistics
On Monday, Orexo AB (0H19:LSE) closed at 22.05, -3.82% below its 52-week high of 22.93, set on Jun 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.93 |
---|---|
High | -- |
Low | -- |
Bid | 20.55 |
Offer | 22.70 |
Previous close | 22.88 |
Average volume | 0.00 |
---|---|
Shares outstanding | 34.71m |
Free float | 27.47m |
P/E (TTM) | -- |
Market cap | 782.72m SEK |
EPS (TTM) | -2.13 SEK |
Data delayed at least 20 minutes, as of May 20 2024 11:58 BST.
More ▼